Surfaxin receives third "approvable" letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Discovery Laboratories' synthetic surfactant receives a third "approvable" letter May 1, despite having reached an agreement on labeling with FDA and successfully completing manufacturing inspection. Discovery submitted Surfaxin (lucinactant) in 2004 for prophylaxis of respiratory distress syndrome in premature infants. The previous approvable letters detailed concerns with product stability and chemistry, manufacturing and controls. The May 1 letter does not cite analytical chemistry methodology, drug product impurity qualification or comparability of the commercial manufacturing process versus that used for the study, Discovery stated, but it does cover CMC issues. According to the firm, FDA requested further clarification of the release and stability biological activity test, tighter acceptance criteria for lipid drug substance impurities and other physical and chemical acceptance criteria, and summary information from certain equipment-related qualification reports. Discovery has scheduled a meeting with FDA to clarify the requests. The firm projects taking 6-8 weeks to complete the response, expected to be a 60-day class 1 resubmission
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.